anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method of deuterated pinocembrin and application of the deuterated pinocembrin in medicines for treating and preventing cerebrovascular diseases such as cerebral apoplexy. The invention discovers that deuterated pinocembrin can be prepared by adopting methods such as a catalytic reduction method, an addition synthesis method and the like, and can obviously improve the neurobehavioral impairment symptom of a cerebral ischemia reperfusion rat, obviously reduce the cerebral infarction volume of the cerebral ischemia reperfusion rat and obviously reduce the cerebral edema degree of the cerebral ischemia reperfusion rat. Meanwhile, the deuterated pinocembrin can obviously relieve the opening degree and permeability of the blood brain barrier of a cerebral hemorrhage rat and reduce cerebral hemorrhage injury. In addition, deuterated pinocembrin has superior pharmacokinetic properties and higher brain tissue concentrations than the proto-pinocembrin drug. The deuterated pinocembrin can be used for preparing medicaments for treating and preventing cerebral apoplexy, and has better effect than the original pinocembrin medicaments. The invention provides an effective solution for treating and preventing stroke diseases.
The proposed clinical trial will evaluate the effects of high molecular weight hylan (Synvisc) injection in comparison with control treatment (saline injection) for osteoarthritis (OA) affecting the temporomandibular joint (TMJ). Patients with TMJ OA of at least three-month duration and who have not responded to conservative treatments will be included. Patients will be randomly assigned to either high molecular hylan injection or control. At baseline and follow up visits, clinical outcome measures will be assessed such as pain and range of motion. Positive findings in clinical outcome measures will provide evidence for the clinical utility of Synvisc in patients with painful TMJ OA. In addition to clinical outcome measures, a sample of synovial fluid from the affected joint will be obtained at the baseline visit and at 12 week follow up, and levels of tumor necrosis factor alpha (TNF alpha), Matrix metalloproteinase (MMP) and Tissue inhibitor of metalloproteinase (TIMP) will be analyzed. By studying the synovial fluid levels of TNF alpha, MMP and TIMP, we will assess the effects of viscosupplementation with Synvisc on the local inflammatory process and proteolytic activity in TMJ OA in comparison with control treatment. Positive findings in clinical symptoms and synovial fluid analysis will also provide implications of clinical utility of Synvisc in patients with painful TMJ OA. Furthermore, this analysis of synovial fluid may identify biomarkers associated with OA affecting the TMJ.
Of the total number of subjects in clinical studies of AVINZA, there were 168 patients age 65 and over, including 64 patients over the age of 74, 100 of whom were treated with AVINZA. Subgroup analyses comparing efficacy were not possible given the small number of subjects in each treatment group. No overall differences in safety were observed between these subjects and younger subjects. In general, caution should be exercised in the selection of the starting dose of AVINZA for an elderly patient, usually starting at the low end of the dosing range. As with all opioids, the starting dose should be reduced in debilitated and non-tolerant patients. (see CLINICAL PHARMACOLOGY, Special Populations, Geriatric, and PRECAUTIONS, Special Risk Groups)
PURPOSE:To obtain a water dissolvable medical preparation of a fat-soluble substance excellent in the solubility, the heat resistance and the acid resistance by incorporating cyclodextrin and acacia and/or charasaponin. CONSTITUTION:After adding 0.1-2.0 times weight acacia and/or 0.01-0.5 times weight charasaponin to cyclodextrin and dissolving the mixture, <=2 times weight fat-soluble substance (e.g. vitamin A or germ oil, etc.) is added for this total amount and the mixture is stirred and mixed. This mixture is diluted with water or polyalcohol, etc. to obtain a liquid water dissolvable medical preparation. Furthermore after drying it with the vacuum drying, a powdery or granular water dissolvable medical preparation of the fat-soluble substance is obtained when the crushing and the classification or the granulation is performed thereto. The storage stability is remarkably increased by adding 0.5-3wt% sodium ascorbate for the preparation prior to the addition of the fat-soluble substance.
Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
<P>PROBLEM TO BE SOLVED: To provide a torpent capable of being readily formulated without having influence on function and shape of a preparation and an external preparation for skin containing the torpent.  <P>SOLUTION: The torpent comprises a glucose derivative, particularly a glucose derivative represented by general formula (I) (wherein R is a residue of 4-methoxyphenol, 4-carboxyphenol or 3-carboxyphenol). The external preparation for skin comprises the torpent. The external preparation for skin may further comprise an irritation causative agent [e.g. an oleagenous agent ingredient such as retinol and its derivative or an ultraviolet light absorber or an antiseptic agent] to the skin.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
A method of purifying Mycoplasma arthritidis mitogen (MAM) to electrophoretic and sequence homogeneity is disclosed. A preparation of MAM purified according to this method was used to determine the sequence of the N-terminal 54 amino acids of MAM. A synthetic peptide consisting of amino acids 15-32 inhibited MAM-induced cell proliferation in vitro. The sequence of the N-terminal 54 amino acids was reverse translated, nucleotide probes were designed therefrom, and the MAM gene was selected from a genomic library. The MAM gene was sequenced and found to be contained on a 1107 bp DNA fragment. The primary translation product contains a 39 amino acid signal sequence and a 213 amino acid mature MAM (molecular weight 25,294). Amino acid sequence comparisons of MAM to bacterial and murine tumor virus superantigens showed regions of conservative sequence homology, including the region capable of inhibiting cell proliferation. Sequence homologies to HIV and other retrovirus proteins and to certain regulatory proteins were also detected. Strategies for blocking or immunizing against certain diseases, including autoimmune diseases, are disclosed.
Ropinirole is a non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. 

Ropinirole has moderate in vitro affinity for opioid receptors. Ropinirole and its metabolites have negligible in vitro affinity for dopamine D1, 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, alpha1-, alpha2-, and beta-adrenoreceptors. 

The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain. This conclusion is supported by studies that show that ropinirole improves motor function in various animal models of Parkinson’s disease. In particular, ropinirole attenuates the motor deficits induced by lesioning the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in primates. The relevance of D3 receptor binding in Parkinson’s disease is unknown.
Cancer stem cells (CSCs) may be eradicated through a novel therapeutic strategy involving, in some embodiments, FDA-approved antibiotics and dietary supplements. The present approach effectively results in the synergistic eradication of CSCs through inhibiting mitochondrial biogenesis in CSCs during induced mitochondrial oxidative stress, without inhibiting normal cells. Embodiments may include a therapeutic agent that inhibits mitochondrial biogenesis and targets the large mitochondrial ribosome, a therapeutic agent that inhibits mitochondrial biogenesis and targets the small mitochondrial ribosome, and a therapeutic agent that behaves as a pro-oxidant or induces mitochondrial oxidative stress. Compositions according to the present approach inhibited CSC propagation by ˜90% in MCF7 ER(+) cell lines during preliminary studies, with confirmed reduction in mitochondrial oxygen consumption and ATP production. Some embodiments include sub-antimicrobial antibiotic concentrations, thereby minimizing antibiotic resistance concerns. In some embodiments, one or more therapeutic agents are conjugated with a targeting signal.
FIELD: biotechnology, medicine, peptides. SUBSTANCE: invention relates to compounds of the general formula R 1 -X-R 2  where X means nonpeptide polymeric spacer and R 1  and R 2  are antagonist of interleukin-1 receptors or inhibitor of tumor necrosis factor. Compounds are synthesized by interaction of R 1  and R 2  containing or modified so that they have reactive cysteine with nonpeptide spacer which is able to form thioester bonds. Muteins are obtained by recombinant technology. EFFECT: decreased rate of elimination of therapeutic agent from body. 36 cl, 24 dwg, 4 tbl, 19 ex
In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
INTRODUCTION: Statins, in the role of anti-cancer agents, have been used in many types of cancers with results in some cases promising while, in others, disappointing.
AREAS COVERED: The purpose of this review is to identify and highlight data from literature on the successes or failure of using statins as anti-cancer agents. We asked ourselves the following two questions:1. Could statins, which are taken mostly to reduce cardiovascular risk, guarantee a lower incidence or a better cancer disease prognosis, concerning local recurrence, metastasis or mortality?2. Does statins intake (before and/or after cancer diagnosis) improve the prognosis or increase the chemotherapeutic action when combined with other anticancer therapies? For the first question twenty-seven manuscripts have been selected, for the second one, twenty-eight.
EXPERT OPINION: There are data which correlate statins with a possible tumor suppressive action among the following cancers: breast, lung, prostate and head and neck. Lastly, for gastric cancer and colorectal there is no evidence of a correlation. The onco-suppressive efficacy of statins is mainly related to the histopathological and/or molecular characteristics of the tumor cells, which have different characteristics.
An association exists between smoking and schizophrenia, independent of other factors and related to psychotic symptomatology. Only a few small descriptive studies have examined the prevalence and correlates of tobacco use among bipolar patients with conflicting results. Patients who smoke score higher on rating scales for psychotic symptoms than their non-smoking peers. While the association of smoking with psychotic symptomatology in schizophrenia is established, such association according to bipolar affective disorder has been reported in a few studies and remains unclear. Also a few studies reported about association of smoking with depressive and manic symptoms, and with suicidal behavior in bipolar patients. Thus further investigation of these issues is warranted.
This invention relates to isolated and purified proteins, such as calreticulin and mimetics and inhibitors of calreticulin, for a novel use of modulating hormone responsiveness. These proteins are useful in gene therapy and in manufacturing pharmaceuticals for treating a variety of diseases, including cancer, osteoporosis and chronic inflammatory disease. The proteins include or bind to an amino acid sequence KXFFYR, wherein X is either G, A or V and Y is either K or R. This sequence is present in the DNA-binding domain, and is critical for the DNA binding activity, of a variety of hormone receptors, including glucocorticoid receptor, minerolcorticoid receptor, androgen receptor, progesterone receptor, estrogen receptor, retinoic acid receptor, thyroid hormone receptor and vitamin D receptor. Proteins which bind to this sequence may inhibit hormone receptor induced gene transcription. Proteins which include this sequence may promote hormone receptor induced gene transcription. The invention includes isolated DNA molecules for these proteins, methods of treating diseases using these proteins, synthetic peptides and their mimetics, and kits containing these proteins, synthetic peptides or their mimetics.
PURPOSE: A composition containing Ulmi Pasta Semen ethanol extract is provided to suppress renal cancer cell proliferation and to effectively prevent and treat renal cancer. CONSTITUTION: A composition for preventing and treating renal cancer contains Ulmi Pasta Semen ethanol extract as an active ingredient, which is prepared by extracting at 50 Deg. C. for 24 hours and decompressing at 45 Deg. C. The composition also contains pharmaceutically acceptable carriers or diluents. A cosmetic composition for preventing renal cancer contains the ethanol extract containing cosmetologically acceptable cosmetic additives. [Reference numerals] (AA) Relative cell survival rate
Participants randomized to the Enhanced Sleep Hygiene (ESH) group will be offered the same CBT-I described above approximately 7 months after being randomized. We will also provide a list of referrals for treatment upon completion of their end of treatment visit (approx. week 11) should they choose to seek treatment sooner. In the interim, they will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms.
The invention discloses composition used for preventing and treating tumor, and a preparation method and an application thereof. The composition is prepared with the raw materials of, by mass: 70-90 parts of aceraceae acer plant seed oil, 10-30 parts of an apricot kernel extract, 0.001-1 part of selenium, and 0.5-5 parts of organic germanium. The preparation method comprises material blending, grinding, degassing, capsule material preparing, pill pressing, forming and drying, pill washing, sorting, and packaging. The composition is used for preparing medicines used for preventing and treating tumors. The composition provided by the invention has selective killing effect against cancer cells, and assists in enhancing immunity and cancer resistance. Compared with existing tumor preventing and treating products, the composition provided by the invention has substantial progress and creativity.
Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
As noncommunicable diseases (NCDs) pose a significant global health burden, identifying effective diagnostic and predictive markers for these diseases is of paramount importance. Epigenetic modifications, such as DNA methylation, have emerged as potential indicators for NCDs. These have previously been exploited in other contexts within the framework of neural network models that capture complex relationships within the data. Applications of neural networks have led to significant breakthroughs in various biological or biomedical fields but these have not yet been effectively applied to NCD modeling. This is, in part, due to limited datasets that are not amenable to building of robust neural network models. In this work, we leveraged a neural network trained on one class of NCDs, cancer, as the basis for a transfer learning approach to non-cancer NCD modeling. Our results demonstrate promising performance of the model in predicting three NCDs, namely, arthritis, asthma, and schizophrenia, for the respective blood samples, with an overall accuracy (f-measure) of 94.5%. Furthermore, a concept based explanation method called Testing with Concept Activation Vectors (TCAV) was used to investigate the importance of the sample sources and understand how future training datasets for multiple NCD models may be improved. Our findings highlight the effectiveness of transfer learning in developing accurate diagnostic and predictive models for NCDs.
Congenital cytomegalovirus (CMV) infection is the main cause of non-hereditary sensorineural hearing loss (SNHL). In order to shed light on SNHL pathophysiology, we examined the auditory pathway in CMV-infected fetuses; the temporal lobe, in particular the auditory cortex, and the inner ear. We investigated both inner ears and temporal lobes of 20 human CMV-infected fetuses at 21 weeks of gestation. As a negative group, five fetuses from spontaneous miscarriages without CMV infection were studied. Inner ears and temporal lobes were histologically examined, immunohistochemistry for CMV and CMV-PCR were performed. On the auditory cortex, we evaluated the local microglial reaction to the infection. CMV-positive cells were found in 14/20 brains and the damage was classified as severe, moderate, or mild, according to histological features. Fetuses with severe brain damage had a statistically higher temporal lobe viral load and a higher number of activated microglial cells in the auditory cortex compared to fetuses with mild brain damage (p: 0.01; p: 0.01). In the inner ears, the marginal cells of the stria vascularis were the most CMV positive. In our study, CMV affected the auditory pathway, suggesting a tropism for this route. In addition, in the auditory cortex, microglial activation may favor further tissue damage contributing to hearing loss.
Patients received thyroid hormone suppression therapy (Euthyrox) . rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
The primary objective of this study is to implement and evaluate an intervention for caregivers of children with spinal cord injury (SCI) ages 7-12. A further objective of this pilot study is to identify which outcomes are being affected by the intervention. Past research has highlighted psychoeducational intervention (i.e., interventions including both educational/skills-building components and psychological support) as most effective in terms of impacting caregiver functioning. The current study will recruit 44 caregivers and their children with SCI. All caregivers will participate in a 2-day Parent Forum, an in-person educational session. Caregivers will then be randomly assigned to receive monthly phone calls from a mental health professional ("intervention group") or no additional targeted support ("control group"). We expect that caregivers who participate in the intervention group and their children will demonstrate better outcomes than caregivers in the control group and their children.
BACKGROUND: The prevalence of frailty and activities of daily living (ADL) disability may be higher in high-altitude Andean regions, due to chronic hypoxia, malnutrition, and physical challenges. and their association is relevant. This study aimed to evaluate the association between frailty and ADL disability among older adults residing in the Totos district in Peru during the year 2022.
METHODS: A cross-sectional study was conducted in Totos district (mean altitude: 3286 m above sea level), located in Ayacucho, Peru, during 2022. A complete census was employed including residents aged 60 and above. The exposure variable was frailty, defined by fulfilling 3 or more criteria of the Fried phenotype. The outcome variable was ADL disability, defined as a score below 95 on the Barthel index. Generalized linear models with a Poisson family, logarithmic link function, and robust variances were employed to estimate crude prevalence ratios and adjusted prevalence ratios (aPRs), along with their corresponding 95% confidence intervals (CIs).
RESULTS: We evaluated 272 older adults with a mean age of 74 years, of whom 59.9% were female, 62.1% were cohabiting or married and 83.1% had not completed primary education. We found that 19.5% were frail, while 51.1% had ADL disability. In the adjusted regression model, we found frailty increased the prevalence of ADL disability (aPR = 1.77; 95%CI: 1.44-2.16; p < 0.001).
CONCLUSION: Frailty was associated with an increased prevalence of ADL disability. These findings could contribute to establishing government intervention plans to manage disability and frailty within the high-risk group comprising older adults living at high altitudes.
PCT No. PCT/EP95/02793 Sec. 371 Date Feb. 27, 1997 Sec. 102(e) Date Feb. 27, 1997 PCT Filed Jul. 17, 1995 PCT Pub. No. WO96/03414 PCT Pub. Date Feb. 8, 1996Antisense oligonucleotides optionally stabilized with phosphorotioate residues or analogues, or modified in the whole sugar-phosphate backbone-complementary to the human urokinase receptor messenger RNA-are able to prevent invasiveness of neoplastic cells by inhibiting the overexpression of the receptor itself, directly responsible of the invasive phenotype. Said oligomers are useful as medicaments for the treatment of primary and secondary neoplasias as well as of other pathologies wherein the urokinase receptor gene overexpression is a pathogenic event.